Alpha 2.0
Login Register
» Authors » H Hyogo

H Hyogo

Explore the profile of H Hyogo including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 12
Citations 58
Followers 0
Related Specialties
Gastroenterology
General Medicine
Oncology
Top 10 Co-Authors
S Tazuma
G Kajiyama
T Nishioka
S Yasumiba
T Kajihara
Y Sunami
H Ochi
G YAMASHITA
Y Hattori
Y Asamoto
Published In
Dig Dis Sci
J Clin Gastroenterol
J Gastroenterol Hepatol
Nihon Shokakibyo Gakkai Zasshi
Med Hypotheses
Affiliations
Soon will be listed here.
Recent Articles
1.
Serum levels of toxic AGEs (TAGE) may be a promising novel biomarker in development and progression of NASH
Takeuchi M, Sakasai-Sakai A, Takata T, Ueda T, Takino J, Tsutsumi M, et al.
Med Hypotheses . 2015 Feb; 84(5):490-3. PMID: 25697114
Nonalcoholic fatty liver disease (NAFLD) ranges from simple steatosis to nonalcoholic steatohepatitis (NASH), leads to fibrosis and potentially cirrhosis, liver failure, and hepatocellular carcinoma, and is one of the most...
2.
A Ligand for peroxisome proliferator-activated receptor gamma inhibits human cholangiocarcinoma cell growth: potential molecular targeting strategy for cholangioma
Kobuke T, Tazuma S, Hyogo H, Chayama K
Dig Dis Sci . 2006 Aug; 51(9):1650-7. PMID: 16927143
Peroxisome proliferator-activated receptor gamma (PPARgamma) ligands have an antitumor effect. The aim of this study was to clarify whether PPARgamma ligands could inhibit the growth of human cholangiocarcinoma cells. PPAR(...
3.
Phospholipid alterations in hepatocyte membranes and transporter protein changes in cholestatic rat model
Hyogo H, Tazuma S, Nishioka T, Ochi H, Yamaguchi A, Numata Y, et al.
Dig Dis Sci . 2001 Oct; 46(10):2089-97. PMID: 11680581
Biliary components are transported by hepatic adenosine triphosphate-binding cassette (ABC) transporters that are located in canalicular membranes. Physiological transporter function is related to membrane fluidity, which is modulated by the...
4.
Factors affecting gallstone recurrence after successful extracorporeal shock wave lithotripsy
Ochi H, Tazuma S, Kajihara T, Hyogo H, Sunami Y, Yasumiba S, et al.
J Clin Gastroenterol . 2000 Oct; 31(3):230-2. PMID: 11034003
Ninety-six patients treated successively for symptomatic cholelithiasis with extracorporeal shock wave lithotripsy (ESWL) and oral bile acid therapy consisting of ursodeoxycholic acid in daily dosages of 600 mg were prospectively...
5.
Biliary excretory function is regulated by canalicular membrane fluidity associated with phospholipid fatty acyl chains in the bilayer: implications for the pathophysiology of cholestasis
Hyogo H, Tazuma S, Kajiyama G
J Gastroenterol Hepatol . 2000 Oct; 15(8):887-94. PMID: 11022829
Background And Aims: Bile canalicular membrane fluidity is modulated by phospholipid molecular species within membrane lipid bilayers. Thus, organellar membrane lipid composition is a determinant of canalicular function. In this...
6.
Role of phospholipase A2 in cholesterol gallstone formation is associated with biliary phospholipid species selection at the site of hepatic excretion: indirect evidence
Hattori Y, Tazuma S, YAMASHITA G, Ochi H, Sunami Y, Nishioka T, et al.
Dig Dis Sci . 2000 Aug; 45(7):1413-21. PMID: 10961723
Phospholipase A2 plays a role in cholesterol gallstone development by hydrolyzing bile phospholipids into lysolecithin and free fatty acids. Lysolecithin and polyunsaturated free fatty acids are known to stimulate the...
7.
Transcytotic vesicle fusion is reduced in cholestatic rats: redistribution of phospholipids in the canalicular membrane
Hyogo H, Tazuma S, Kajiyama G
Dig Dis Sci . 1999 Sep; 44(8):1662-8. PMID: 10492150
Cholestasis, which affects phospholipid trafficking, therefore would be expected to alter canalicular membrane phospholipid composition and fluidity, as well as fatty acid composition of membrane phospholipid. These alterations may affect...
8.
Effects of cerivastatin sodium, a new HMG-CoA reductase inhibitor, on biliary lipid metabolism in patients with hypercholesterolemia
Tazuma S, YAMASHITA G, Ochi H, Miura H, Kajihara T, Hattori Y, et al.
Clin Ther . 1998 Jul; 20(3):477-85. PMID: 9663363
The use of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors has become common in the treatment of hypercholesterolemia. The present uncontrolled study was undertaken to determine the effect of cerivastatin sodium...
9.
A combination therapy with simvastatin and ursodeoxycholic acid is more effective for cholesterol gallstone dissolution than is ursodeoxycholic acid monotherapy
Tazuma S, Kajiyama G, Mizuno T, YAMASHITA G, Miura H, Kajihara T, et al.
J Clin Gastroenterol . 1998 Jul; 26(4):287-91. PMID: 9649013
Inhibitors of 3-hydroxy,3-methylglutaryl coenzyme A (HMG-CoA) reductase have been reported to decrease the cholesterol saturation index (CSI) in duodenal bile in humans and to prevent formation of cholesterol gallstones in...
10.
A quantitative assessment of serum chylomicron by light scattering intensity: application to the intestinal fat absorption test
Tazuma S, Miura H, Hirano N, Hattori Y, Kajihara T, Tsuchimoto D, et al.
J Gastroenterol Hepatol . 1998 Jan; 12(11):713-8. PMID: 9430035
A novel fat absorption test to clarify the malabsorption syndrome was developed using a micronephelometric technique and compared with the classic conventional technique using 131I-triolein. An integrity of time-sequential light...